REGN vs STRL · P/E 14, rev $14.34B vs P/E 75, rev $2.12B
Regeneron Pharmaceuticals Inc (REGN) versus Sterling Construction Company Inc (STRL) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Sterling Construction Company Inc (STRL) is a engineering & construction company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported STRL revenue for 2024-12-31 was $2.12B. Net income was $270.9M. Revenue was up 7.3% from 2023-12-31 to 2024-12-31. STRL currently screens at market cap $25.72B and trailing P/E 75.2.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. STRL currently screens at market cap $25.72B and trailing P/E 75.2.
Not investment advice. Open the REGN and STRL stock pages for the full models.
Not investment advice.